For SLNs taken from patients with HER2+ breast carcinomas, we observed SA-β-gal positive tumor cells (SA-β-gal high (+ +) and low (+)) in 100% of the SLN metastases, and high SA-β-gal positivity (+ +) in 87.5% of the samples (Table 5). This evidence concerns the gene ERBB2 and neoplasm.